RUNX3 Suppresses Migration, Invasion and Angiogenesis of Human Renal Cell Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chen, Feifei ^a   Bai, Jin ^a   Li, Wang ^a   Mei, Pengjin ^a   Liu, Hui ^a   Li, Linlin ^a   Pan, Zhenqiang ^a,b   Wu, Yongping ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; TRANSCRIPTION FACTOR RUNX3; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; ENZYME REPRESSION; FEMALE; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; RUNX3 GENE; TISSUE MICROARRAY; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; ZYMOGRAPHY;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CORE BINDING FACTOR ALPHA 3 SUBUNIT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874012134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056241     Document Type: Article

References (26)

1. Volpe A, Patard JJ, (2010) Prognostic factors in renal cell carcinoma. World J Urol 28: 319-327.
2. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566.
3. Cohen HT, McGovern FJ, (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-2490.
4. Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, et al. (1993) PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A 90: 6859-6863.
5. Lund AH, van Lohuizen M, (2002) RUNX: a trilogy of cancer genes. Cancer Cell 1: 213-215.
6. Bae SC, Choi JK, (2004) Tumor suppressor activity of RUNX3. Oncogene 23: 4336-4340.
7. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, et al. (2009) Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
8. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, et al. (2005) Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11: 6479-6488.
9. Zhang Z, Chen G, Cheng Y, Martinka M, Li G, (2011) Prognostic significance of RUNX3 expression in human melanoma. Cancer 117: 2719-2727.
10. Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, et al. (2009) Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 16: 1686-1694.
11. Peng Z, Wei D, Wang L, Tang H, Zhang J, et al. (2006) RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 12: 6386-6394.
12. Mei PJ, Bai J, Liu H, Li C, Wu YP, et al. (2011) RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137: 1823-1830.
13. Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, et al. (1995) Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene 159: 245-248.
14. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, et al. (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124.
15. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, et al. (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520.
16. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, et al. (2008) Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 7: 94.
17. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, et al. (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84: 479-484.
18. Pennison M, Pasche B, (2007) Targeting transforming growth factor-beta signaling. Curr Opin Oncol 19: 579-585.
19. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, et al. (1985) Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A 82: 119-123.
20. Connolly EC, Freimuth J, Akhurst RJ, (2012) Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 8: 964-978.
21. Rundhaug JE, (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9: 267-285.
22. Deryugina EI, Quigley JP, (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34.
23. Stephenson CP, Karanges E, McGregor IS, (2012) Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry.
24. Degue S, Simon TR, Basile KC, Yee SL, Lang K, et al. (2012) Moving Forward by Looking Back: Reflecting on a Decade of CDC's Work in Sexual Violence Prevention, 2000-2010. J Womens Health (Larchmt).
25. Martin MD, Matrisian LM, (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26: 717-724.
26. Cao Y, E G, Wang E, Pal K, Dutta SK, et al. (2012) VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 72: 3912-3918.